Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates
Nine-Month Key Financial HighlightsTotal revenues of €116.6 million, including product sales of €112.5 millionNet Profit of €24.7 million, including proceeds from the Priority Review Voucher (PRV) 1sale Operating profit of €34.2 million compared to an operating loss of €57.2 million in the first nine-months of 2023Cash position of €156.3 million Includes €61.2 million in gross proceeds from recent private placement 2 Lower cash burn expected in the second half of 2024 as...
Nasdaq GlobeNewswire
07/11/2024
Zealand Pharma Announces Financial Results for the First Nine Months of 2024
Company announcement – No. 49 / 2024 Zealand Pharma Announces Financial Results for the First Nine Months of 2024Continued strong progress across obesity pipeline with proprietary assets ready for Phase 2 backed by a solid financial position. Presented extremely encouraging weight loss and tolerability data with long-acting amylin analog petrelintide from MAD Part 2 (16-week trial) at ObesityWeek 2024Announced positive topline results with GLP-1R/GLP-2R dual agonist dapiglutide...
Nasdaq GlobeNewswire
07/11/2024
Approx. USD 4.0 M Invested in Product Development for NTDs - GHIT's First…
In order to overcome this situation, the GHIT Fund has decided to invest approximately JPY 280 million (USD 2.0 million1) in a project led by US-based non-profit organization Drugs & Diagnostics for Tropical Diseases (DDTD), in collaboration with Medical & Biological Laboratories, Co. Ltd. (MBL) in Japan, The Carter Center (TCC, USA), and Big Eye Diagnostics, Inc. (BEDx, USA), with active support from the Centers for Disease Control and Prevention (CDC), to develop a Rapid Diagnostic…
PR Newswire
07/11/2024
This World Prematurity Day, Pampers is empowering the 82%[1] of parents who feel…
Fortunately, with the right information and support from neonatal professionals, parents can build confidence and be empowered to become partners in their babies' day-to-day care with essential interactions that support bonding. This approach is known as Family Integrated Care (FiCare), an important advancement in neonatal care, which positively impacts infant development, and improve the mental health of parents. Fortunately, with the right information and support from neonatal…
PR Newswire
07/11/2024
Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma…
Key Takeaways from the Severe Asthma Pipeline Report Key Takeaways from the Severe Asthma Pipeline Report Request a sample and discover the recent advances in severe asthma treatment drugs @ Severe Asthma Pipeline Report The severe asthma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage severe asthma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an...
PR Newswire
06/11/2024
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights 10/31/2024100,093,87388,569,210For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,
[email protected]
Patricia Sosa Navarro, Chief of Staff to the...
Nasdaq GlobeNewswire
06/11/2024
DBV Technologies Reports Third Quarter 2024 Financial Results
DBV Technologies Reports Third Quarter 2024 Financial ResultsDBV closes Q3 2024 with a cash balance of $46.4 million; cash runway into Q1 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J200), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter of 2024. The quarterly and nine months financial statements were approved by the Board of Directors on November 6, 2024. Financial Highlights...
Nasdaq GlobeNewswire
06/11/2024
Nyxoah Reports Third Quarter Financial and Operating Results
REGULATED INFORMATIONNyxoah ReportsThird Quarter Financial and OperatingResults FDA approval on trackfor first quarter 2025 , U.S. commercial team build out in progress Companyfully funded with cash until mid 2026Mont-Saint-Guibert, Belgium –November 6 , 2024,10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq:...
Nasdaq GlobeNewswire
06/11/2024
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024…
ROCKVILLE, MD, November 6, 2024— MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced its financial results for the third quarter ended September 30, 2024, and updated its 2024 guidance. Third Quarter and Recent HighlightsTotal revenue of $8.2 million in the third quarter of 2024, an increase of 2%...
Nasdaq GlobeNewswire
06/11/2024
Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
"Jazz once again delivered record revenues of more than $1.05 billion and a 14% year-over-year increase in revenue from our key growth drivers combined. We continue to see robust patient demand for Xywav with approximately 400 net patient additions in the third quarter, supported by physician and patient appreciation of a low-sodium treatment option. Strong sleep1 performance coupled with continued Epidiolex performance gives us confidence in maintaining our total revenue guidance of $4.0…
PR Newswire
06/11/2024
Interim Report Q3 2024: Further margin expansion and strong cash flow despite…
HighlightsThe Hearing division continued to gain significant market share leading to 10% organic revenue growth, while the divisional profit margin increased by 5.9 percentage points to 34.8%The Enterprise division was negatively impacted by sell-in pressure due to economic growth challenges in parts of Central Europe, while North America and Rest of World continued its stabilization. Overall, organic revenue growth ended at -7%, while sell-out growth was -3%. Despite the topline...
Nasdaq GlobeNewswire
06/11/2024
Update of financial guidance for 2024
GN has throughout the year increased its earnings power and cash flow generation, leading to an upgrade of the guidance on free cash flow excl. M&A to “DKK >1,100 million” and a confirmation of the EBITA margin guidance of “12 to 13%”. Following a somewhat softer market development than earlier anticipated for Enterprise and Gaming, GN adjusts its organic revenue growth guidance to “1% to 2%” Financial guidance for 2024Organic revenue growthReported EBITA marginFree cash...
Nasdaq GlobeNewswire
06/11/2024
With CAGR of 4.6 %, Eyelash Adhesives Market Size to Reach $2.97 Billion…
Overview of Report Findings Overview of Report Findings Download Sample Pages of Research analysis: https://www.theinsightpartners.com/sample/TIPRE00027378/ Market Segmentation Competitive Strategy and Development Global Headlines on Eyelash Adhesives Purchase Premium Copy of Global Eyelash AdhesivesMarketGrowth Report at:https://www.theinsightpartners.com/buy/TIPRE00027378/ Conclusion The global eyelash adhesives market is driven by several...
PR Newswire
06/11/2024
Genmab Announces Financial Results for the First Nine Months of 2024
November 6, 2024 Copenhagen, Denmark;Interim Report for the First Nine Months Ended September 30, 2024Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapyGenmab announced that it will assume sole responsibility for the continued development and potential...
Nasdaq GlobeNewswire
06/11/2024
Antimicrobial Susceptibility Testing Market to hit USD 5.68 billion by 2029 with…
Browse in-depth toc on "Antimicrobial Susceptibility Testing Market" Browse in-depth toc on "Antimicrobial Susceptibility Testing Market" 240 - tables56 - figures282 - pages Consumables segment accounted for the largest share of the antimicrobial susceptibility testing market. Based on the product segment, the consumables market is segmented into culture media and growth media, mic strips, susceptibility disks, and susceptibility plates. In 2023, the largest market...
PR Newswire
06/11/2024
Virbac : Declaration of the number of shares and voting rights 10/2024
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers)Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577DateTotal number of shares representing the share capitalTotal number of voting rightsOctober, 31 20248 390 660Gross total of voting rights :...
Nasdaq GlobeNewswire
06/11/2024
BRACCO TRIPLES PRODUCTION OF ITS INNOVATIVE CONTRAST AGENT FOR ULTRASOUND IN…
PLAN-LES-OUATES, Switzerland, Nov. 6, 2024 /PRNewswire/ -- Over 80 million euros have been invested to build Hexagon, a new manufacturing facility located next to the historical 1997 plant which will, when fully operational, triple the production and distribution of one of the leading products from Bracco's research. The new multi-functional building will supply the world with the innovative contrast agent for ultrasound based on microbubbles, which allows real-time diagnosis and offers greater…
PR Newswire
06/11/2024
BrainTransporter™ dramatically improves antibody delivery to the brain
Brain uptake of biotherapeutics such as antibodies and enzymes is severely limited by the blood brain barrier (BBB) primarily due to their size. Active transport across the BBB, using one of the body's own delivery mechanisms, aims to enable better drug uptake into the brain. The BT technology utilizes the Transferrin Receptor (TfR), a protein facilitating transport across the BBB, to optimize brain delivery. Brain uptake of biotherapeutics such as antibodies and enzymes is severely limited...
PR Newswire
06/11/2024
KFSHRC Implements Advanced Technology for Single-Step Cancerous Tissue…
RIYADH, Saudi Arabia, Nov.06, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) in Madinah has successfully implemented a novel technology, Large-Format Tissue Processing (Supa Mega Block). This technology accelerates examining cancerous tissues post-removal, ensuring the complete excision of all affected areas in a single step. This process results in time savings, cost reduction, and an enhanced patient experience, making KFSHRC-Madinah the first...
Nasdaq GlobeNewswire
06/11/2024
IM Cannabis to Report Third Quarter 2024 Financial Results on Thursday, November…
If you are unable to join us live, a recording of the call will be available on our website at https://investors.imcannabis.com/ within 24 hours after the call. If you are unable to join us live, a recording of the call will be available on our website athttps://investors.imcannabis.com/within 24 hours after the call. Link for the to register for the zoom call:https://us02web.zoom.us/webinar/register/WN_1McuNcK_R62gmx7a3BplLg#/registration About IM Cannabis Corp. IMC (Nasdaq:...
PR Newswire
06/11/2024
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by…
For an accessible version of this Press Release, please visit www.tevapharm.com Q3 2024 revenues of $4.3 billion reflect an increase of 13% in U.S. dollars, or 15% in local currency terms, compared to Q3 2023.AUSTEDO ®– shows continued growth, U.S. revenues of $435 million in Q3 2024, an increase of 28% compared to Q3 2023; reaffirming 2024 revenue outlook of ~$1.6 billion.AJOVY ®– global revenues of $137 million in Q3 2024, an increase of 21% in local currency terms compared to...
Nasdaq GlobeNewswire
06/11/2024
Dallah Hospital Al Nakheel Achieves Global Healthcare Accreditation, Reinforcing…
"We are immensely proud of achieving GHA Accreditation," said Dr. Salah R. Elfaqih, Chief Medical Officer at Dallah Health. "This prestigious recognition not only validates our ongoing efforts to enhance patient safety and care but also positions us as a key player in the global medical travel market. GHA Accreditation provides us with a framework to continuously improve our services for international patients and benchmark ourselves against the world's best. The rigorous…
PR Newswire
06/11/2024
MEGAROBO Unveils High-Content Cell Imaging System for Advanced Multidimensional…
In addition, the CellVue™ T2000 has been fully incorporated into AutoBio™, the laboratory automation system developed by MEGAROBO. This integration enables a fully automated workflow from cell seeding, passaging and drug delivery to image detection and analysis. In addition, the CellVue™ T2000 has been fully incorporated into AutoBio™, the laboratory automation system developed by MEGAROBO. This integration enables a fully automated workflow from cell seeding, passaging and drug delivery to...
PR Newswire
06/11/2024
Esaote Group expands production in India
The new Esaote manufacturing site will produce – for the Indian market - a full range of advanced ultrasound series - My Lab™ A, My Lab™ E series and Compact Portable Ultrasounds - as "Made in India", which will be marketed shortly after completion of regulatory and quality assurance processes by the relevant local bodies. The newEsaote manufacturing sitewill produce – for the Indian market -a full range of advanced ultrasound series-My Lab™ A,My Lab™ E seriesandCompact...
PR Newswire
06/11/2024
Altri Comunicati
